Lucentis (Ranibizumab) | EyeKnow O.D.

Approved uses

Neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization

0.5 mg (0.05 mL of the 10 mg/mL strength) intravitreally once a month; for myopic CNV, up to three months with retreatment as needed

The higher of the two strengths; myopic CNV is the only one with a defined stopping point

Diabetic macular edema and diabetic retinopathy

0.3 mg (0.05 mL of the 6 mg/mL strength) intravitreally once a month

The diabetic indications use the LOWER strength, 0.3 mg rather than 0.5 mg, at the same 0.05 mL volume

Contraindications

Ocular or periocular infections Hypersensitivity.

Available Forms

Intravitreal injection, single-dose prefilled syringe delivering 0.05 mL: 0.5 mg (10 mg/mL) and 0.3 mg (6 mg/mL).

Mechanism of Action

Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.